These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15933426)

  • 1. Prostate cancer relapse after therapy with curative intention: a diagnostic and therapeutic dilemma.
    Gronau E; Goppelt M; Harzmann R; Weckermann D
    Onkologie; 2005 Jun; 28(6-7):361-6. PubMed ID: 15933426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease.
    Zietman AL; Dallow KC; McManus PA; Heney NM; Shipley WU
    Urology; 1996 Feb; 47(2):236-9. PubMed ID: 8607241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
    Ward JF; Blute ML; Slezak J; Bergstralh EJ; Zincke H
    J Urol; 2003 Nov; 170(5):1872-6. PubMed ID: 14532796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prostate specific antigen in individual cancer checkups and in therapeutic treatment].
    Recker F
    Ther Umsch; 2006 Feb; 63(2):135-41. PubMed ID: 16514966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PSA recurrence after primary curative therapy--local or systemic? When is a second curative therapy still possible?].
    Wirth MP; Engelhardt FM
    Urologe A; 2005 Sep; 44(9):997-1004, 1006-7. PubMed ID: 16133232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage options for biochemical recurrence after primary therapy for prostate cancer.
    Bong GW; Keane TE
    Can J Urol; 2007 Dec; 14 Suppl 1():2-9. PubMed ID: 18163938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSA relapse prostate cancer: the importance of tailored therapy.
    Aranha O; Vaishampayan U
    Urol Oncol; 2004; 22(1):62-9. PubMed ID: 14969807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
    Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
    Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of men with rising prostate-specific antigen levels following radical prostatectomy.
    Tzou K; Tan WW; Buskirk S
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):125-36. PubMed ID: 21166517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer.
    Vis AN; Schröder FH; van der Kwast TH
    Eur Urol; 2006 Aug; 50(2):258-65. PubMed ID: 16413660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of PSA doubling time to monitor prostate cancer recurrence.
    Wieder JA; Belldegrun AS
    Mayo Clin Proc; 2001 Jun; 76(6):571-2. PubMed ID: 11393493
    [No Abstract]   [Full Text] [Related]  

  • 14. [First results of PET / CT-guided secondary lymph node surgery on patients with a PSA relapse after radical prostatectomy].
    Winter A; Uphoff J; Henke RP; Wawroschek F
    Aktuelle Urol; 2009 Sep; 40(5):294-9. PubMed ID: 19533582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy.
    Stephenson AJ; Eastham JA
    J Clin Oncol; 2005 Nov; 23(32):8198-203. PubMed ID: 16278473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L.
    Yu H; Diamandis EP; Wong PY; Nam R; Trachtenberg J
    J Urol; 1997 Mar; 157(3):913-8. PubMed ID: 9072598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [PSA and follow-up after treatment of prostate cancer].
    Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
    Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Markers and meaning of primary treatment failure.
    Swindle PW; Kattan MW; Scardino PT
    Urol Clin North Am; 2003 May; 30(2):377-401. PubMed ID: 12735513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rising Prostate Specific Antigen following treatment with curative intention].
    Jakobsen H; Pedersen KV
    Ugeskr Laeger; 2007 May; 169(20):1907-9. PubMed ID: 17553369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.